Highlights from

AAN 2019

American Academy of Neurology annual meeting

Philadelphia, USA 4-10 May 2019

Non-invasive vagus nerve stimulation for cluster headache

Non-invasive vagus nerve stimulation (nVNS) was cleared in 2018 by the FDA for adjunctive use for the prophylaxis of cluster headache. Real-world findings from a patient registry showed that nVNS usually reduced pain severity within 30 minutes, complementing evidence from clinical trials supporting its efficacy for acute treatment of episodic cluster headache attacks [1].

Participants were trained on self-treatment with nVNS and the use of a tracker for data collection on nVNS usage and frequency, severity, and duration of cluster headache attacks. A total of 14 patients used nVNS for 116 attacks, with a mean of 3.69 stimulations used per attack. At attack onset and 30 minutes after initial treatment, mean pain score was 2.68 and 1.30, respectively, on a scale of 0-4. Patients subjectively self-reported that nVNS reduced pain in 82% of attacks. Of the 116 nVNS-treated attacks, 69.8% had resolved to either mild or no pain after 30 minutes.

  1. Nagy A, et al. AAN 2019, S38.006.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.